Rovi is a Madrid pharmaceutical group known for low-molecular-weight heparins and long-acting injectables; its bemiparin trials in cancer-associated thrombosis are why it appears among phase 3 cancer sponsors.
Laboratorios Farmacéuticos Rovi, founded in 1946 in Madrid and listed on the Spanish stock exchange, makes the low-molecular-weight heparin bemiparin, contract-manufactures injectables and develops long-acting formulations. Its phase 3 trials of bemiparin for preventing and treating venous thromboembolism in cancer patients are registered on ClinicalTrials.gov under Rovi as lead sponsor.